Literature DB >> 24677542

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.

Rosine Saleh1, Ghaith Wedeh2, Harald Herrmann3, Siham Bibi1, Sabine Cerny-Reiterer4, Irina Sadovnik5, Katharina Blatt5, Emir Hadzijusufovic6, Sylvie Jeanningros1, Catherine Blanc7, Magali Legarff-Tavernier8, Elise Chapiro8, Florence Nguyen-Khac8, Frédéric Subra1, Patrick Bonnemye8, Patrice Dubreuil9, Vanessa Desplat10, Hélène Merle-Béral8, Michael Willmann11, Thomas Rülicke12, Peter Valent4, Michel Arock13.   

Abstract

In systemic mastocytosis (SM), clinical problems arise from factor-independent proliferation of mast cells (MCs) and the increased release of mediators by MCs, but no human cell line model for studying MC activation in the context of SM is available. We have created a stable stem cell factor (SCF) -dependent human MC line, ROSA(KIT WT), expressing a fully functional immunoglobulin E (IgE) receptor. Transfection with KIT D816V converted ROSA(KIT WT) cells into an SCF-independent clone, ROSA(KIT D816V), which produced a mastocytosis-like disease in NSG mice. Although several signaling pathways were activated, ROSA(KIT D816V) did not exhibit an increased, but did exhibit a decreased responsiveness to IgE-dependent stimuli. Moreover, NSG mice bearing ROSA(KIT D816V)-derived tumors did not show mediator-related symptoms, and KIT D816V-positive MCs obtained from patients with SM did not show increased IgE-dependent histamine release or CD63 upregulation. Our data show that KIT D816V is a disease-propagating oncoprotein, but it does not activate MCs to release proinflammatory mediators, which may explain why mediator-related symptoms in SM occur preferentially in the context of a coexisting allergy. ROSA(KIT D816V) may provide a valuable tool for studying the pathogenesis of mastocytosis and should facilitate the development of novel drugs for treating SM patients.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24677542     DOI: 10.1182/blood-2013-10-534685

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.

Authors:  Hyun Don Yun; Martin Felices; Daniel A Vallera; Peter Hinderlie; Sarah Cooley; Michel Arock; Jason Gotlib; Celalettin Ustun; Jeffrey S Miller
Journal:  Blood Adv       Date:  2018-07-10

2.  Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

Authors:  Olivier Lortholary; Marie Olivia Chandesris; Cristina Bulai Livideanu; Carle Paul; Gérard Guillet; Ewa Jassem; Marek Niedoszytko; Stéphane Barete; Srdan Verstovsek; Clive Grattan; Gandhi Damaj; Danielle Canioni; Sylvie Fraitag; Ludovic Lhermitte; Sophie Georgin Lavialle; Laurent Frenzel; Lawrence B Afrin; Katia Hanssens; Julie Agopian; Raphael Gaillard; Jean-Pierre Kinet; Christian Auclair; Colin Mansfield; Alain Moussy; Patrice Dubreuil; Olivier Hermine
Journal:  Lancet       Date:  2017-01-07       Impact factor: 79.321

3.  A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.

Authors:  Melody C Carter; Avanti Desai; Hirsh D Komarow; Yun Bai; Sarah T Clayton; Alicia S Clark; Karina N Ruiz-Esteves; Lauren M Long; Daly Cantave; Todd M Wilson; Linda M Scott; Olga Simakova; Mi-Yeon Jung; Jamie Hahn; Irina Maric; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2017-06-16       Impact factor: 10.793

Review 4.  Midostaurin: a magic bullet that blocks mast cell expansion and activation.

Authors:  P Valent; C Akin; K Hartmann; T I George; K Sotlar; B Peter; K V Gleixner; K Blatt; W R Sperr; P W Manley; O Hermine; H C Kluin-Nelemans; M Arock; H-P Horny; A Reiter; J Gotlib
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

5.  CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

Authors:  Georg Greiner; Nadine Witzeneder; Angelika Berger; Klaus Schmetterer; Gregor Eisenwort; Ana-Iris Schiefer; Simone Roos; Theresia Popow-Kraupp; Leonhard Müllauer; Johannes Zuber; Veronika Sexl; Lukas Kenner; Wolfgang R Sperr; Peter Valent; Matthias Mayerhofer; Gregor Hoermann
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

6.  The Phosphatidylserine and Phosphatidylethanolamine Receptor CD300a Binds Dengue Virus and Enhances Infection.

Authors:  Xavier Carnec; Laurent Meertens; Ophélie Dejarnac; Manuel Perera-Lecoin; Mohamed Lamine Hafirassou; Jiro Kitaura; Rasika Ramdasi; Olivier Schwartz; Ali Amara
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

7.  Dengue virus-elicited tryptase induces endothelial permeability and shock.

Authors:  Abhay Ps Rathore; Chinmay Kumar Mantri; Siti Ab Aman; Ayesa Syenina; Justin Ooi; Cyril J Jagaraj; Chi Ching Goh; Hasitha Tissera; Annelies Wilder-Smith; Lai Guan Ng; Duane J Gubler; Ashley L St John
Journal:  J Clin Invest       Date:  2019-07-02       Impact factor: 14.808

8.  Use of humanized rat basophilic leukemia reporter cell lines as a diagnostic tool for detection of allergen-specific IgE in allergic patients: time for a reappraisal?

Authors:  Franco H Falcone; Marcos J C Alcocer; Yoshimi Okamoto-Uchida; Ryosuke Nakamura
Journal:  Curr Allergy Asthma Rep       Date:  2015-11       Impact factor: 4.806

9.  CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.

Authors:  Niklas Mueller; Daniel Wicklein; Gregor Eisenwort; Mohamad Jawhar; Daniela Berger; Gabriele Stefanzl; Georg Greiner; Alexandra Boehm; Christoph Kornauth; Leonhard Muellauer; Susanne Sehner; Gregor Hoermann; Wolfgang R Sperr; Philipp B Staber; Ulrich Jaeger; Johannes Zuber; Michel Arock; Udo Schumacher; Andreas Reiter; Peter Valent
Journal:  Blood       Date:  2018-07-17       Impact factor: 22.113

Review 10.  New Insights into the Pathogenesis of Systemic Mastocytosis.

Authors:  Zhixiong Li
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.